Ranibizumab As Needed Therapy For Wet Age-Related Macular Degeneration Combined With Serous Pigment Epithelial Detachment

Ding Xu,Chun Zhao,Xu Luo,Jing Yu,Fang Wang

2016-01-01

Abstract:Purpose: To evaluate the effect of ranibizumab on wet age-related macular degeneration (wAMD) combined with serous pigment epithelium detachment (PED). Design: Retrospective, noncomparative case series. Methods: Thirteen eyes of 13 patients with wAMD and associated serious PED were included in the study. All the patients were treated with intravitreal ranibizumab as needed from the first injection and followed up for 12 months. The follow-up data included the best-corrected ETDRS letter score, maximum PED height, PED area and PED volume, and central retinal thickness (CRT) on ocular coherence tomography (OCT). Results: The mean ETDRS letter score was 57.54 +/- 10.28 at the last visit compared to 46.69 +/- 11.58 at the baseline (t = -3.47, P < 0.05). The mean change of the ETDRS letter score was 10.85 +/- 10.84. The mean maximum PED height, area and volume at the baseline and month 12 were 342.38 +/- 176.39 mu m and 189.23 +/- 134.69 mu m (z = -2.83, P < 0.05), 5.12 +/- 4.69 mm(2) and 2.74 +/- 2.89 mm(2) (z = -2.67, P < 0.05), 1.07 +/- 1.73 mm(3) and 0.25 +/- 0.46 mm(3) (z = -2.90, P < 0.05), respectively. The CRT were decreased from 331.54 +/- 60.08 mu m at the baseline to 286.85 +/- 82.47 mu m at month 12 (t = 1.85, P > 0.05). The mean number of injections during the study period was 3.3 +/- 1.1. Conclusions: Intravitreal ranibizumab as needed for treatment of wAMD combined with sPED was shown to be effective.